

# Development and validation of a prognostic nomogram for adult patients with renal sarcoma: A retrospective study based on the SEER database

**Yongkun Zhu**

Southeast University

**Weipu Mao**

Southeast University

**Guangyuan Zhang**

Affiliated Zhongda Hospital of Southeast University

**Si Sun**

Southeast University

**Shuchun Tao**

Southeast University

**Tiancheng Jiang**

Southeast University

**Qingbo Wang**

Affiliated the Second Hospital of Nanjing, Nanjing University of Chinese Medicine

**Jianping Wu**

Affiliated Zhongda Hospital of Southeast University

**Ming Chen** (✉ [mingchenseu@126.com](mailto:mingchenseu@126.com))

Affiliated Zhongda Hospital of Southeast University

---

## Research Article

**Keywords:** adult, renal sarcoma, nomogram, SEER, prognosis

**Posted Date:** April 15th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1550819/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Background

Renal sarcoma (RS) is rarely seen in clinical practice. The purpose of this study was to develop a prognostic nomogram model, which could predict the probability of overall survival (OS) and cancer-specific survival (CSS) in adult patients with RS.

## Methods

Patients diagnosed with RS were recruited from the SEER database between 2004 and 2015, and randomized to two cohorts: the training cohort and the validation cohort. Uni- and multivariate Cox regression analyses in the training cohort were used to screen independent prognostic factors for OS and CSS. Prognostic nomograms for OS and CSS were created separately for adult RS patients based on independent risk factors. The area under the receiver operating characteristic (ROC) curves, calibration curves, and DCA (Decision curve analysis) were used to validate the nomograms.

## Results

A total of 232 eligible patients were recruited, including 162 in the training cohort and 70 in the validation cohort. Sex, histological type, SEER stage, and surgery were independent prognostic factors for OS, while histological type, SEER stage, surgery, chemotherapy were independent prognostic factors for CSS. Based on the above independent prognostic factors, prognostic nomograms for OS and CSS were created respectively. In the training cohort, the AUCs of the nomograms for OS and CSS were 0.742 and 0.733, respectively. In the validation cohort, the AUCs of the nomograms for OS and CSS were 0.837 and 0.758, respectively. The calibration curves of the nomograms showed high consistencies between the predicted and actual survival rates. Finally, the DCA demonstrated that the nomograms in the wide high-risk threshold had a higher net benefit than the SEER stage.

## Conclusion

A prognostic nomogram for renal sarcoma was created and validated for reliability and usefulness in our study, which assisted urologists in accurately assessing the prognosis of adult RS patients.

## 1. Introduction

Sarcomas are a heterogeneous group of tumors arising in the embryonic mesoderm, accounting for approximately 1% of all malignant tumors, of which less than 5% occur in the urogenital tract (1). Primary renal sarcoma (RS) accounts for around 24.6% of all genitourinary sarcomas (1) and less than 1% of all primary kidney tumors(2). Renal sarcoma is not only very rare but also leads to a poor prognosis: the

overall 1-, 3-, and 5-year survival rate was 86.3%, 40.7%, and 14.5%, respectively, and the median survival was 28 months (3). According to previous reviews and case reports, renal sarcoma could be classified into the following pathological types: liposarcoma(4), leiomyosarcoma(5), carcinosarcoma(6), rhabdomyosarcoma(7), clear cell sarcoma(8), fibrosarcoma(9) and others, and different pathological types predict distinct prognosis.

RS is currently poorly studied as it is such a rare malignancy. As a result, an accurate prognostic model for RS is essential for both urologists and patients. In fact, the SEER stage grading system was employed by urologists to measure the progression of RS, which includes localized, regional, distant, and unstaged(10, 11). However, other factors including sex, age, race, marital status, radiation, chemotherapy, surgery, etc. may also have an impact on prognosis due to individual variances. In recent years, nomograms have been increasingly employed in clinical practice for cancer prognosis. It has been regarded as a useful statistical prediction tool for benefiting both clinicians and patients(12, 13). So far, there is no report on the application of nomograms in predicting the prognosis of renal sarcoma in adults. In the present study, based on data from the SEER database between 2004 and 2015, nomograms were set up to predict survival outcomes for adult patients with RS and their reliability was also validated.

## **2. Materials And Methods**

### **2.1 Data sources**

Data were extracted from the Surveillance Epidemiology and End Results (SEER) database (<https://seer.cancer.gov/>), which is supported by the Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS). SEER statistics are collected on a national scale, with information from 18 states that represent all regions of the country covering 28% of the US population, including sociodemographic factors, geographic variables, clinical factors, cancer-specific factors, pathologic variables, treatment factors, and outcomes(14). The SEER database is openly accessed, and all authors have obtained permission. SEER\*Stat software (Version 8.3.9.2 - August 20, 2021, SEER\*Stat Software (cancer.gov)) was used to extract the data.

### **2.2 Patients**

A total of 367 patients diagnosed with RS between 2004–2015 were established according to the International Classification of Disease for Oncology, Third Edition [ICD-O-3] site codes, including liposarcoma (8850/3,8851/3,8852/3,8853/3,8858/3,8860/3), leiomyosarcoma (8890/3, 8891/3, 8896/3), carcinosarcoma (8980/3), rhabdomyosarcoma (8900/3, 8901/3, 8910/3), clear cell sarcoma (8964/3), fibrosarcoma (8810/3), sarcoma, NOS (8800/3). The exclusion criteria are based on the following principles: (1) Age at diagnosis is below 18 years old, n = 62;(2) Unknown marital status at diagnosis, n = 18;(3) Unknown Race, n = 1;(4) Unknown Survival months, n = 1;(5) Not the first malignant primary tumor, n = 53. Finally, 232 eligible patients were included in the analytic cohort. The flow chart of the selection process was presented in Fig. 1.

## 2.3 Variables and endpoints

The following variables were filtered from the SEER database: age, sex, marital status, grade, histological type, SEER stage, surgery, radiotherapy, chemotherapy. To facilitate the next step of data analysis, the categorical variables were coded directly, and for continuous variables, they were first converted to categorical variables before coding. Some of the variables are explained below:

1. Regarding age, patients were divided into two categories: older than 60 years and less than or equal to 60.
2. Regarding grade, it was defined as follows: well-differentiated (Grade I); moderately differentiated (Grade II); poorly differentiated (Grade III); undifferentiated (Grade IV); and unknown grade.
3. Regarding the stage of SEER, patients were classified into four subgroups according to the progression of the sarcoma, including localized, regional, distant, and unstaged.

The death and RS-specific death were regarded as observed endpoints. OS refers to the period between the start of the study and death from any cause, and survivors are censored as of the last follow-up. CSS refers to the period between the commencement of the study and the death due to RS, with deaths due to other causes or survivors omitted.

## 2.4 Statistical methods

Using the random sampling without replacement method, the sample was divided into training and validation cohorts in the split of 7:3. The training cohort was enrolled to create nomograms and screen factors for nomograms, while the validation cohort was utilized to verify the outcome of the training cohort. The univariate and multivariate COX regression analyses of OS and CSS rates were carried out to obtain the independent prognostic variables. The hazard ratio (95% CI) and P-value also were calculated. The nomograms based on the included variables were established to predict the OS and CSS probability over 3 and 5 years. Draw a vertical line down the scale for each variable from a given adult RS patient, and the place where it intersects with the "Points" line represents the variable's score. The overall score was calculated by adding the scores for each variable. Find the matching score on the "Total points" line, project it to the OS and CSS lines below, and the result is the probability of 3-, 5- OS and CSS for the individual.

The area under the ROC curves was utilized to verify the discriminative capabilities of the nomograms. The area under curve (AUC) is defined as the area enclosed by the ROC curve and the coordinate axis, and the value range of AUC is usually between 0.5 and 1. The diagnostic value of the nomogram was represented by AUC. Calibration curves were used to evaluate the prediction performance of nomograms. A bootstrap with 1000 resamples was put to use in these tests. The DCA was operated to confirm the usability of the nomograms in comparison to the SEER stage.

SPSS 26.0 (IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp.) was applied to conduct statistical analysis for univariate and multivariate COX regression. The

nomograms were developed and validated by exerting the rms, hmisc, lattice, survival, formula, ggplot2, pROC, timeROC, and rmda packages in R version 4.1.2 (<http://www.r-project.org/>).  $P < 0.05$  (two-sided) was considered statistically significant.

## 3. Results

### 3.1 Baseline demographic and clinical characteristics

A total of 232 eligible patients diagnosed with RS between 2004–2015 were included in our study, which were divided into two cohorts randomly: the training cohort (162) and the validation cohort (70). The number of RS patients aged over or equal to 60 and under 60 was similar in the total cohort. Most RS patients were female (54.7%), married (57.3%), and white (81.1%). Grade IV accounts for the largest proportion of known grades. Of the other general type, the majority were leiomyosarcoma (40.9%) and localized (34.1%). Most RS adult patients received radiotherapy (85.3%) and chemotherapy (76.7%), but only a few had undergone surgery (22.4%). Specific baseline demographic and clinical characteristics information are represented in Table 1.

Table 1  
Baseline demographic and clinical characteristics with adult renal sarcoma patients in our study.

Characteristic	Total No. (%)	The training cohort	The validation cohort
		No. (%)	No. (%)
Total	232(100)	162 (70.0)	70(30.0)
Age, years			
≤ 60	120(51.7)	79 (48.8)	41(58.6)
> 60	112(48.3)	83 (51.2)	29(41.4)
Sex			
Male	105(45.3)	72 (44.4)	33(47.1)
Female	127(54.7)	90 (55.6)	37(52.9)
Marital status			
Married	133(57.3)	89 (54.9)	44(62.9)
Unmarried	99(42.7)	73 (45.1)	26(37.1)
Race			
White	188(81.1)	134 (82.7)	54(77.1)
Black	27(11.6)	17 (10.5)	10(14.3)
Others	17(7.3)	11 (6.8)	6(8.6)
Grade			
Grade I	22(9.5)	14 (8.5)	8(11.4)
Grade II	22(9.5)	16 (9.9)	6(8.6)
Grade III	39(16.8)	28 (17.3)	11(15.7)
Grade IV	67(28.9)	49 (30.2)	18(25.7)
Unknown	82(35.3)	55 (34.0)	27(38.6)
Histological type			
Liposarcoma	69(29.7)	52 (32.1)	17(24.3)
Leiomyosarcoma	95(40.9)	60 (37.0)	35(50.0)
Carcinosarcoma	10(4.3)	6 (3.7)	4(5.7)

Characteristic	Total No. (%)	The training cohort	The validation cohort
		No. (%)	No. (%)
Rhabdomyosarcoma	4(1.7)	3 (1.9)	1(1.4)
Clear cell sarcoma	19(8.3)	12 (7.4)	7(10.0)
Fibrosarcoma	2(0.9)	2 (1.2)	0
Sarcoma, NOS	33(14.2)	27 (16.7)	6(8.6)
SEER stage			
Localized	79(34.1)	56 (34.6)	23(32.9)
Regional	70(30.2)	43 (26.5)	27(38.6)
Distant	73(31.5)	54 (33.3)	19(27.1)
Unstaged	10(4.2)	9 (5.6)	1(1.4)
Surgery			
Yes	52(22.4)	40 (24.7)	12(17.1)
No/Unknown	180(77.6)	122 (75.3)	58(82.9)
Radiotherapy			
Yes	198(85.3)	138 (85.2)	60 (85.7)
No/Unknown	34(14.7)	24 (14.8)	10(14.3)
Chemotherapy			
Yes	178(76.7)	123 (75.9)	55(78.6)
No/Unknown	54(23.3)	39 (24.1)	15(21.4)

## 3.2 Univariate and multivariate analysis of OS and CSS

The univariate and multivariate COX regression analysis of OS and CSS rates in the training cohort was carried out for screening independent prognostic variables. Age, sex, marital status, grade, histological type, SEER stage, surgery, radiotherapy, and chemotherapy were the nine variables included in our analysis. By univariate regression analysis, it was shown that all variables mentioned above might be substantially linked with OS and CSS. Meanwhile, it was also shown that sex, histological type, SEER stage, and surgery were independent predictive variables for OS by multivariate analysis, while histological type, SEER stage, surgery, and chemotherapy were independent prognostic variables for CSS.

Confidence intervals (CI) and corresponding p-values for specific variables in the univariate and multivariate analyses of OS and CSS were summarized in Tables 2 and 3, respectively.

Table 2  
Univariate and multivariate analysis of overall survival (OS) rates in the training cohort.

Characteristic	Univariate analysis		Multivariate analysis	
	Hazard Ratio (95% CI)	P value	Hazard Ratio (95% CI)	P value
Age, years				
≤ 60	Reference		Reference	
> 60	1.469 (1.000-2.159)	0.050	-	0.098
Sex				
Male	Reference		Reference	
Female	0.601 (0.409–0.881)	0.009	0.498 (0.328–0.756)	0.001
Marital status				
Married	Reference		Reference	
Unmarried	0.869 (0.592–1.277)	0.475	-	0.745
Race				
White	Reference		Reference	
Black	0.453 (0.219–0.935)	0.032	-	0.038
Others	1.217 (0.561–2.641)	0.619	-	0.868
Grade				
Grade I	Reference		Reference	
Grade II	1.489 (0.355–6.240)	0.586	-	0.091
Grade III	3.301 (0.960-11.349)	0.058	-	0.752
Grade IV	5.251 (1.619–17.025)	0.006	-	0.205
Unknown	5.779 (1.791–18.647)	0.003	-	0.498
Histological type				
Liposarcoma	Reference		Reference	
Leiomyosarcoma	1.364 (0.839–2.219)	0.210	1.406 (0.854–2.315)	0.181
Carcinosarcoma	7.253 (2.936–17.919)	< 0.001	6.996 (2.703–18.107)	< 0.001

**Abbreviations:**

CSS, Cancer-specific survival; SEER, Surveillance, Epidemiology, and End Results; HR, hazard ratio; CI, confidence interval.

<b>Characteristic</b>	<b>Univariate analysis</b>		<b>Multivariate analysis</b>	
Rhabdomyosarcoma	2.590 (0.783–8.562)	0.119	3.797 (1.127–12.789)	0.031
Clear cell sarcoma	1.063 (0.480–2.353)	0.880	0.542 (0.232–1.266)	0.157
Fibrosarcoma	0.701 (0.095–5.170)	0.728	0.374 (0.050–2.809)	0.339
Sarcoma, NOS	1.910 (1.061–3.437)	0.031	1.563 (0.843–2.898)	0.157
<b>SEER stage</b>				
Localized	Reference		Reference	
Regional	2.769 (1.599–4.794)	< 0.001	3.623 (2.047–6.410)	< 0.001
Distant	4.793 (2.861–8.029)	< 0.001	4.317 (2.487–7.494)	< 0.001
Unstaged	2.444 (0.924–6.462)	0.072	1.936 (0.645–5.805)	0.239
<b>Surgery</b>				
No/Unknown	Reference		Reference	
Yes	0.478 (0.313–0.728)	0.001	0.515 (0.313–0.847)	0.009
<b>Radiotherapy</b>				
Yes	Reference		Reference	
No/Unknown	0.875 (0.521–1.471)	0.615	-	0.771
<b>Chemotherapy</b>				
Yes	Reference		Reference	
No/Unknown	0.679 (0.444–1.038)	0.074	-	0.348
<b>Abbreviations:</b>				
CSS, Cancer-specific survival; SEER, Surveillance, Epidemiology, and End Results; HR, hazard ratio; CI, confidence interval.				

Table 3

Univariate and multivariate analysis of cancer-specific survival (CSS) rates in the training cohort.

Characteristic	Univariate analysis		Multivariate analysis	
	Hazard Ratio (95% CI)	P value	Hazard Ratio (95% CI)	P value
Age, years				
≤ 60	Reference		Reference	
> 60	2.101 (1.144–3.859)	0.017	-	0.083
Sex				
Male	Reference		Reference	
Female	0.838 (0.466–1.507)	0.556	-	0.767
Marital status				
Married	Reference		Reference	
Unmarried	0.714 (0.394–1.294)	0.267	-	0.256
Race				
White	Reference		Reference	
Black	0.538 (0.192–1.508)	0.238	-	0.433
Others	0.749 (0.180–3.117)	0.691	-	0.652
Grade				
Grade I	-		-	
Grade II	Reference		Reference	
Grade III	2.378 (0.493–11.461)	0.280	-	0.919
Grade IV	4.481 (1.044–19.228)	0.044	-	0.153
Unknown	3.624 (0.836–15.713)	0.085	-	0.698
Histological type				
Liposarcoma	Reference		Reference	
Leiomyosarcoma	2.088 (0.802–5.437)	0.132	2.225 (0.839–5.901)	0.108
Carcinosarcoma	24.382 (7.227–82.262)	< 0.001	23.815 (6.516–87.039)	< 0.001

**Abbreviations:**

CSS, Cancer-specific survival; SEER, Surveillance, Epidemiology, and End Results; HR, hazard ratio; CI, confidence interval.

Characteristic	Univariate analysis		Multivariate analysis	
Rhabdomyosarcoma	3.799 (0.456–31.661)	0.217	9.022 (0.995–81.826)	0.051
Clear cell sarcoma	3.740 (1.198–11.676)	0.023	2.686 (0.825–8.740)	0.101
Fibrosarcoma	3.026 (0.363–25.224)	0.306	4.303 (0.446–41.551)	0.207
Sarcoma, NOS	5.748 (2.165–15.262)	< 0.001	4.816 (1.712–13.547)	< 0.001
SEER stage				
Localized	Reference		Reference	
Regional	3.106 (1.214–7.948)	0.018	3.926 (1.492–10.328)	0.006
Distant	7.031 (2.988–16.547)	< 0.001	5.867 (2.301–14.962)	< 0.001
Unstaged	4.656 (1.201–18.049)	0.026	1.800 (0.379–8.557)	0.460
Surgery				
No/Unknown	Reference		Reference	
Yes	0.350 (0.191–0.639)	0.001	0.352 (0.168–0.739)	0.006
Radiotherapy				
Yes	Reference		Reference	
No/Unknown	0.950 (0.425–2.127)	0.901	-	0.518
Chemotherapy				
Yes	Reference		Reference	
No/Unknown	0.889 (0.450–1.756)	0.735	2.315 (1.065–5.033)	0.034
<b>Abbreviations:</b>				
CSS, Cancer-specific survival; SEER, Surveillance, Epidemiology, and End Results; HR, hazard ratio; CI, confidence interval.				

### 3.3 Nomogram development and validation

According to the independent prognostic variables of OS and CSS, the nomograms were established, respectively (represented in Fig. 2). In the OS nomogram, the SEER stage contributed the most to survival outcome, while the histological type contributed the least. In the CSS nomogram, the SEER stage was the most significant predictor of survival, followed by histological type.

As shown in Fig. 3, the ROC curves were drawn, and the AUC of the OS nomogram was significantly greater than that of the SEER stage in the training cohort (nomogram 0.742, SEER stage 0.698), while in

the validation cohort the AUC of the OS nomogram was similar to SEER stage (nomogram 0.837, SEER 0.833). However, the AUCs of the nomograms for CSS were considerably higher than those of the SEER stage both in the training cohort (nomogram 0.733, SEER stage 0.656) and validation cohort (nomogram 0.758, SEER stage 0.656). By comprising of the above ROC curves, it was demonstrated that the nomogram had more diagnostic value than the SEER stage to discriminate the survival probability of adult RS patients.

The AUCs for 3- and 5-OS were 0.751 and 0.757, respectively, and 0.779 and 0.750 for 3- and 5-CSS, respectively, in the training cohort. The validation cohort AUCs for 3- and 5-OS were 0.775 and 0.829, respectively, and 0.807 and 0.855, respectively, for 3- and 5-CSS. As shown in Fig. 4, the nomograms accurately predict the probability of 3- and 5- OS and CSS for adult RS patients.

The calibration curves of the nomograms showed high consistencies between the predicted and actual survival rates both in the training and validation cohorts, illustrated in Fig. 5 and Supplementary Fig. 1. The gray line in the calibration curves represents the ideal reference line, where the predicted survival probability matches the actual survival probability. The presentation of the nomograms was represented by red dots. The DCA demonstrated that the nomograms in the wide high-risk threshold had a higher net benefit than the SEER stage (shown in Fig. 6), which validated the superiority of the nomogram utility over the SEER stage in clinical practice.

## 4. Discussion

As mentioned above, adult renal sarcomas are an extremely rare group of tumors, accounting for only 0.8% of primary renal tumors(3). The SEER stage grading system was used by urologists to evaluate the progression of renal sarcomas. Sarcomas are classified into different grades based on the location and the extent to which it invades organs, blood vessels, and lymph nodes, including localized, regional, distant, and unstaged. However, due to the influence of individual differences, such as sex, age, race, marital status, radiation, chemotherapy, surgery, etc., it is not comprehensive enough to use the extent of tumor invasion alone to evaluate the prognosis for adult RS patients.

The nomogram is a graphical representation of a clinical prediction model that calculates a total score based on the values of individual predictor variables, and then predicts the risk of an event or the probability of survival based on the total score(15). It is a novel prediction model that is gradually sought after by clinicians. In recent years, predictions for the prognosis of various urinary cancer with nomograms have been reported more and more. For instance, Wu et al. employed a genomic-clinicopathologic nomogram to predict preoperative lymph node metastasis in bladder cancer(16); A nomogram was conducted by Mao et al. to predict prognosis in patients with lung metastatic renal cell carcinoma(17). Zhang et al. established a radiomics nomogram to predict bone metastasis in newly diagnosed prostate cancer patients(18). The nomogram and Aggtrmmns scoring system were utilized by Zhou et al. for predicting overall survival and cancer-specific survival of kidney cancer patients(19).

As it is known that compared with the SEER stage, nomogram has the following advantages: 1. By combining various independent risk factors according to the patient's condition, it allows for a more intuitive assessment and individualization of the patient's prognosis (20). 2. It quantifies the possibility of OS and CSS in patients, permitting a more precise prognostic evaluation (21). Therefore, for the first time, the prognostic nomograms were developed for adult RS patients to obtain personalized and accurate prognostic predictions in this study.

We extracted data from the SEER database for adult RS patients and used COX univariate and subsequent multivariate regression analysis to conclude that histological type, SEER stage, surgery were independent risk factors for OS and CSS. Based on the multivariate regression analysis, the OS and CSS nomograms were constructed, respectively. Subsequently, we validated the nomograms. The area under the ROC curves for 3-, 5- OS were 0.775 and 0.829, respectively, and 0.807 and 0.855 for 3-, 5- CSS, respectively, which depicted that the nomograms accurately predict the probability of 3- and 5- OS and CSS for adult RS patients. The calibration curves showed high consistencies between the predicted and actual survival rates.

From the nomograms, it was suggested that RS patients without surgery, with distant SEER stage grade, and histological type of fibrosarcoma had the poorest prognosis. Depending on histological type, the prognosis from good to the poor was liposarcoma, leiomyosarcoma, carcinosarcoma, rhabdomyosarcoma, clear cell sarcoma, and fibrosarcoma. According to the Kaplan-Meier overall and disease-specific survival analysis of patients with RS established by Nazemi et al. (1), liposarcoma had the greatest prognosis, followed by leiomyosarcoma and clear cell sarcoma, while carcinosarcoma had the worst prognosis. Regardless of carcinosarcoma, its prognostic ranking was consistent with ours. However, it was shown that carcinosarcoma had the worst prognosis, which was inconsistent with our analysis. The reason for this may be that rhabdomyosarcoma and fibrosarcoma were not included in the Kaplan-Meier analysis due to the small sample size in their study, thus leading to biased results.

In addition, our study demonstrated that surgical treatment for adult RS patients may effectively reduce the risk of death. This is in line with the findings of Moreira DM et al. (22) and Öztürk H (23). Moreover, it is also found that chemotherapy may also improve the prognosis of adult RS patients. Chemotherapy has now been applied clinically to treat advanced or recurrent renal sarcoma, although not standardized (24), and the latest research of Yakirevich E et al. suggested that comprehensive genomic analysis of adult RS patients may provide new opportunities for targeted therapy (25).

To our surprise, our data suggested radiotherapy was not an independent prognostic factor for the adult patient with renal sarcoma, which was in accordance with the findings of Li et al. (26). However, Gamboa et al. reported that preoperative radiotherapy may improve the prognosis by making some tumors easier to resect (27). Thus, the prognostic impact of radiotherapy on patients with renal sarcomas should be further explored. The clinical outcome of primary adult renal sarcoma is extremely poor and the optimal treatment remains to be debated. Further studies are needed to verify whether it is surgery or combination therapy that works best. Furthermore, our data also suggested that female patients had a better

prognosis than male patients, which could be attributed to differences in female anatomy or hormone levels.

We appraised the prognosis of adult RS patients with nomograms for the first time, which adds a new dimension to our research. Simultaneously, using the SEER database excluded the influencing factors of single-center. Even so, there are still a few flaws in our study: 1. Because of the rarity of renal sarcoma, limited sample size is inevitable and therefore our findings may not be representative; 2. As our study is retrospective, there is a lack of multicenter data for external validation. 3. Due to the lack of data in the SEER database, genetic factors, laboratory findings, and medication history were not included in our study.

## 5. Conclusions

In conclusion, a prognostic nomogram was created to predict overall survival (OS) and cancer-specific survival (CSS) for adult patients with RS, and their reliability and usefulness were also validated in our study. We anticipate that our study will facilitate urologists in accurately assessing the prognosis of adult RS patients and provide support for further clinical trials.

## Abbreviations

RS

Renal sarcoma

SEER

Surveillance, Epidemiology, and End Results

OS

Overall survival

CSS

Cancer-specific survival

DCA

Decision curve analysis

ICD-O

The International Classification of Diseases for Oncology

ROC

Receiver operating characteristic

AUC

Area under the curve

HR

Hazard ratios

CI

Confidence intervals.

# Declarations

## *Ethics approval and consent to participate*

Not applicable.

## *Consent for publication*

Not applicable.

## *Availability of data and materials*

The datasets analyzed during the current study are available in the Surveillance Epidemiology and End Results database. (<https://seer.cancer.gov/>)

## *Competing interests*

The authors declare that they have no competing interests.

## *Funding*

This study was funded by Natural Science Foundation of China (82170703); Natural Science Foundation of China (82100732); Natural Science Foundation of Jiangsu Province (BK20200360); Excellent Youth Development Fund of Zhongda Hospital, SEU (2021ZDYQQPY04).

## *Authors' contributions*

Study designing: YZ, MC, JW, and QW; Administrative support: MC, JW, and QW; Data Collection: YZ, WM, GZ, SS, ST, TJ; Statistical analysis and graphs production: YZ, WM, GZ, SS; Draft writing: YZ, WM, GZ; Final Revision: All authors.

## *Acknowledgements*

The authors thank all the patients and investigators involved in this work, as well as the developers of the SEER database.

# References


1. Nazemi A, Daneshmand S. Adult genitourinary sarcoma: A population-based analysis of clinical characteristics and survival. *Urologic Oncology: Seminars and Original Investigations*. 2020;38(5):334–43. DOI: 10.1016/j.urolonc.2019.12.004
2. Vogelzang NJ, Fremgen AM, Guinan PD, Chmiel JS, Sylvester JL, Sener SF. Primary renal sarcoma in adults. A natural history and management study by the American Cancer Society, Illinois Division. *Cancer*. 1993;71(3):804–10. DOI: 10.1002/1097-0142(19930201)71:3<804::aid-cncr2820710324>3.0.co;2-a

3. Wang X, Xu R, Yan L, Zhuang J, Wei B, Kang D, et al. Adult Renal Sarcoma: Clinical Features and Survival in a Series of Patients Treated at a High-volume Institution. *Urology*. 2011;77(4):836–41. DOI: 10.1016/j.urology.2010.09.028
4. Mayes DC, Fechner RE, Gillenwater JY. Renal liposarcoma. *Am J Surg Pathol*. 1990;14(3):268–73. DOI: 10.1097/00000478-199003000-00008
5. Ding Y, Quan C. Primary Renal Leiomyosarcoma. *J Coll Physicians Surg Pak*. 2021;30(6):725–7. DOI: 10.29271/jcpsp.2021.06.725
6. Chiu K-C, Lin M-C, Liang Y-C, Chen C-Y. Renal carcinosarcoma: case report and review of literature. *Ren Fail*. 2008;30(10):1034–9. DOI: 10.1080/08860220802403192
7. Seabury JC. Renal rhabdomyosarcoma. *JAMA*. 1967;201(13):1043–4.
8. Aw SJ, Chang KTE. Clear Cell Sarcoma of the Kidney. *Arch Pathol Lab Med*. 2019;143(8):1022–6. DOI: 10.5858/arpa.2018-0045-RS
9. Agarwal K, Singh S, Pathania OP. Primary renal fibrosarcoma: a rare case report and review of literature. *Indian J Pathol Microbiol*. 2008;51(3):409–10. DOI: 10.4103/0377-4929.42541
10. Chen C, Jiang X, Xia F, Chen X, Wang W. Clinicopathological Characteristics and Survival Outcomes of Primary Renal Leiomyosarcoma. *Front Surg*. 2021;8:704221. DOI: 10.3389/fsurg.2021.704221
11. Zhuge Y, Cheung MC, Yang R, Perez EA, Koniaris LG, Sola JE. Pediatric non-Wilms renal tumors: subtypes, survival, and prognostic indicators. *J Surg Res*. 2010;163(2):257–63. DOI: 10.1016/j.jss.2010.03.061
12. Chen J, Chen J, Yang B, Liu Z, Huang X, Liu G, et al. Predicting sentinel lymph node metastasis in a Chinese breast cancer population: assessment of an existing nomogram and a new predictive nomogram. *Breast Cancer Res Treat*. 2012;135(3):839–48. DOI: 10.1007/s10549-012-2219-x
13. Lee CK, Asher R, Friedlander M, Gebiski V, Gonzalez-Martin A, Lortholary A, et al. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. *Eur J Cancer*. 2019;117:99–106. DOI: 10.1016/j.ejca.2019.05.029
14. Doll KM, Rademaker A, Sosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. *JAMA Surg*. 2018;153(6):588. DOI: 10.1001/jamasurg.2018.0501
15. Iasonos A, Schrag D, Raj GV, Panageas KS. How To Build and Interpret a Nomogram for Cancer Prognosis. *JCO*. 2008;26(8):1364–70. DOI: 10.1200/JCO.2007.12.9791
16. Wu S-X, Huang J, Liu Z-W, Chen H-G, Guo P, Cai Q-Q, et al. A Genomic-clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. *EBioMedicine*. 2018;31:54–65. DOI: 10.1016/j.ebiom.2018.03.034
17. Mao W, Fu Z, Wang K, Wu J, Xu B, Chen M. Prognostic nomogram for patients with lung metastatic renal cell carcinoma: a SEER-based study. *Ann Palliat Med*. 2021;10(3):2791–804. DOI: 10.21037/apm-20-1488
18. Zhang W, Mao N, Wang Y, Xie H, Duan S, Zhang X, et al. A Radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients. *European Journal of Radiology*.

2020;128:109020. DOI: 10.1016/j.ejrad.2020.109020

19. Zhou Y, Zhang R, Ding Y, Wang Z, Yang C, Tao S, et al. Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer. *Cancer Medicine*. 2020;9(8):2710–22. DOI: 10.1002/cam4.2916
20. Hou G, Zheng Y, Wei D, Li X, Wang F, Tian J, et al. Development and validation of a SEER-based prognostic nomogram for patients with bone metastatic prostate cancer. *Medicine (Baltimore)*. 2019;98(39):e17197. DOI: 10.1097/MD.00000000000017197
21. Wang K, Xu X, Xiao R, Du D, Wang L, Zhang H, et al. Development and validation of a nomogram to predict cancer-specific survival in patients with hypopharyngeal squamous cell carcinoma treated with primary surgery. *J Int Med Res*. SAGE Publications Ltd; 2021;49(12):03000605211067414. DOI: 10.1177/03000605211067414
22. Moreira DM, Gershman B, Thompson RH, Okuno SH, Robinson SI, Leibovich BC, et al. Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study. *Urologic Oncology: Seminars and Original Investigations*. 2015;33(12):505.e15-505.e20. DOI: 10.1016/j.urolonc.2015.07.022
23. Öztürk H. Prognostic features of renal sarcomas (Review). *Oncology Letters*. 2015;9(3):1034–8. DOI: 10.3892/ol.2014.2838
24. Blas L, Roberti J. Primary Renal Synovial Sarcoma and Clinical and Pathological Findings: a Systematic Review. *Curr Urol Rep*. 2021;22(4):25. DOI: 10.1007/s11934-021-01038-w
25. Yakirevich E, Madison R, Fridman E, Mangray S, Carneiro BA, Lu S, et al. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. *European Urology Oncology*. 2021;4(2):282–8. DOI: 10.1016/j.euo.2019.04.002
26. Li L, Liang J, Song T, Yin S, Zeng J, Zhong Q, et al. A Nomogram Model to Predict Prognosis of Patients With Genitourinary Sarcoma. *Frontiers in Oncology [En ligne]*. 2021 [cité le 7 mars 2022];11. Disponible: <https://www.frontiersin.org/article/10.3389/fonc.2021.656325>
27. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. *CA: A Cancer Journal for Clinicians*. 2020;70(3):200–29. DOI: 10.3322/caac.21605

## Figures




**Figure 1**

The study flow chart of the selection process


**Figure 2**

The prognostic nomograms for predicting 3- and 5- OS and CSS probabilities of adult RS patients in the training cohort. (A) OS nomogram; (B) CSS nomogram.




**Figure 3**

ROC curves of nomograms and the SEER stage for predicting OS and CSS probabilities in the training and validation cohort. ROC for OS(A) and CSS (B) in the training cohort, respectively; ROC for OS(C) and CSS(D) in the validation cohort, respectively




**Figure 4**

ROC curves for predicting 3-,5- OS and CSS probabilities in the training and validation cohort. ROC for 3-,5- OS(A) and CSS (B)in the training cohort; ROC for 3-,5- OS (C) and CSS (D)in the validation cohort.



**Figure 5**

Calibration curves for verifying the consistency between predicted 3-,5- OS and CSS and actual 3-,5- OS and CSS in the training cohort. 3- OS(A) and 5- OS(B) calibration curves; 3- CSS(C) and 5- CSS(D) calibration curves.



**Figure 6**

DCA curves for validating the clinical utility of the nomograms. DCA curves for OS(A) and CSS(B) in the training cohort. DCA curves for OS (C) and CSS(D) in the validation cohort.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [analysisdata.xlsx](#)
- [origindata.xlsx](#)
- [SupplementaryFigure1.tif](#)